The DOI matches its Crossref record.
A Phase II trial of Belinostat ( PXD 101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma
Open accessAbstract
Summary: Belinostat is a pan‐histone deacetylase inhibitor with antitumour and anti‐angiogenic properties. An open label, multicentre study was conducted in patients with peripheral T‐cell lymphoma ( PTCL ) or cutaneous T‐cell lymphoma ( CTCL ) who failed ≥1 prior systemic therapy and were treated with belinostat (1000 mg/m 2 intravenously ×5 d of a 21‐d cycle). The primary endpoint was objective response rate ( ORR ). Patients with PTCL ( n = 24) had received a median of three prior systemic therapies (range 1–9) and 40% had stage IV disease. Patients with CTCL ( n = 29) had received a median of one prior skin‐directed therapy (range 0–4) and four prior systemic therapies (range 1–9); 55% had stage IV disease. The ORR s were 25% ( PTCL ) and 14% ( CTCL ). Treatment‐related adverse events occurred in 77% of patients; nausea (43%), vomiting (21%), infusion site pain (13%) and dizziness (11%) had the highest incidence. Treatment‐related serious adverse events were Grade 5 ventricular fibrillation; Grade 4 thrombocytopenia; Grade 3 peripheral oedema, apraxia, paralytic ileus and pneumonitis; and Grade 2 jugular vein thrombosis. Belinostat monotherapy was well tolerated and efficacious in patients with recurrent/refractory PTCL and CTCL . This trial was registered at www.clinicaltrials.gov as NCT 00274651.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
O'Connor, O. A., Horwitz, S., Masszi, T., Van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.2782 · Cited by 555
Self-citationRecent developments of HDAC inhibitors: Emerging indications and novel molecules
Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14889 · Cited by 416
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Histone deacetylase 6 in cancer
Li, T., Zhang, C., Hassan, S., Liu, X., Song, F., Chen, K., Zhang, W., & Yang, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0654-9 · Cited by 326
The role of altered protein acetylation in neurodegenerative disease
Kabir, F., Atkinson, R., Cook, A. L., Phipps, A. J., & King, A. E. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1025473 · Cited by 75
Metadata
- Authors
- Foss, F., Advani, R., Duvic, M., Hymes, K. B., Intragumtornchai, T., Lekhakula, A., Shpilberg, O., Lerner, A., Belt, R. J., Jacobsen, E. D., Laurent, G., Ben‐Yehuda, D., Beylot‐Barry, M., Hillen, U., Knoblauch, P., Bhat, G., Chawla, S., Allen, L. F., & Pohlman, B.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2014-11-17
- Volume
- 168
- Issue
- 6
- Pages
- 811-819
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2084393474
- Cited by
- 193
- References
- 0
- FWCI
- 18.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase II trial of Belinostat ( PXD 101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma. https://app.cochat.ai/papers/10.1111/bjh.13222
- The paper
- Foss, F., Advani, R., Duvic, M., Hymes, K. B., Intragumtornchai, T., Lekhakula, A., Shpilberg, O., Lerner, A., Belt, R. J., Jacobsen, E. D., Laurent, G., Ben‐Yehuda, D., Beylot‐Barry, M., Hillen, U., Knoblauch, P., Bhat, G., Chawla, S., Allen, L. F., & Pohlman, B. (2015). A Phase II trial of Belinostat ( PXD 101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma. British Journal of Haematology. https://doi.org/10.1111/bjh.13222
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.